European specialty pharma company

A European specialty pharmaceutical company was established to focus on the commercialisation of pharmaceuticals and rejuvenating established medicines. By 2020, the company acquired an ex-blockbuster specialty Biologic and began working with one of the world’s largest financial investors.

In 2020, the E3 Life team started advising the company on its growth and acquisition strategy, helping the company to identify, due diligence, and complete four transformative acquisitions including the build up of a US commercial platform and three specialty oncology pharmaceutical assets.

The expertise of E3 Life has helped the unrealised enterprise value of this European specialty pharmaceutical company to multiply several times over.